Department of Clinical Pharmacy, Jining No. 1 People's Hospital, Jining Medical University, Jining, Shandong, China.
The State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China.
Biomed Res Int. 2020 May 20;2020:3905719. doi: 10.1155/2020/3905719. eCollection 2020.
The relationship between diabetes mellitus (DM) and Alzheimer's disease (AD) has attracted wide attention. Studies have reported that ginsenoside Rb1 can improve human cognitive ability and glucose tolerance during the development of diabetes. The mechanism behind the improvement in cognitive ability and glucose tolerance still remains unclear. In this study, streptozotocin- (STZ-) injected mice were used as models to explore the mechanisms behind the cognitive improvement of ginsenoside Rb1. According to the results of behavioral tests, ginsenoside Rb1 improved memory and cognitive ability of STZ-lesioned mice. In addition to that, ginsenoside Rb1 also relieved glucose intolerance induced by STZ injection by enhancing insulin sensitivity. These beneficial effects of ginsenoside Rb1 is most likely mediated by upregulating the expression of NMDAR1 and IDE in the hippocampus through inhibiting the activity of Cdk5/p35. This work will be of great importance in illustrating the mechanisms of ginsenoside Rb1 for improving cognitive ability, as well as revealing the relationship between diabetes and AD.
糖尿病（DM）和阿尔茨海默病（AD）之间的关系引起了广泛关注。有研究报道称，人参皂苷 Rb1 可在糖尿病发展过程中提高人类认知能力和葡萄糖耐量。但其改善认知能力和葡萄糖耐量的机制仍不清楚。本研究采用链脲佐菌素（STZ）注射小鼠作为模型，探讨人参皂苷 Rb1 改善认知能力的机制。根据行为测试结果，人参皂苷 Rb1 改善了 STZ 损伤小鼠的记忆和认知能力。此外，人参皂苷 Rb1 通过增强胰岛素敏感性缓解了 STZ 注射引起的葡萄糖不耐受。人参皂苷 Rb1 的这些有益作用可能是通过抑制 Cdk5/p35 的活性来上调海马 NMDAR1 和 IDE 的表达介导的。这项工作对于阐明人参皂苷 Rb1 改善认知能力的机制以及揭示糖尿病和 AD 之间的关系具有重要意义。
